查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837481

骨关节炎疼痛治疗市场按产品类型、给药途径、通路、最终用户、患者年龄层和疾病严重程度划分－2025-2032年全球预测

Osteoarthritis Pain Drug Market by Product Type, Route Of Administration, Distribution Channel, End User, Patient Age Group, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，骨关节炎止痛药市场将成长至 143.3 亿美元，复合年增长率为 6.67%。

主要市场统计数据
基准年 2024 85.4亿美元
预计年份：2025年 91.2亿美元
预测年份：2032年 143.3亿美元
复合年增长率 (%) 6.67%

本书策略性地介绍了不断发展的骨关节炎疼痛治疗领域，重点阐述了临床要务、患者多样性以及相关人员的实用创新路径。

由于患者需求各异、慢性疼痛病程复杂，以及不同年龄层和疾病严重程度的患者功能受损程度不同，骨关节炎仍是一个复杂的临床挑战。临床医生和支付方越来越倾向于寻求能够快速缓解症状、长期使用安全且能显着改善活动能力和生活品质的治疗方法。近期的临床创新主要集中在完善现有的药物分类，并探索新的机制，以解决在持久控制疼痛和延缓疾病进展方面存在的持续性不足。

在此背景下，製造商正在调整研发重点，着重于差异化的给药方式、提升老年族群的安全性，以及开发适合门诊和居家照护模式的解决方案。同时，医疗系统和专科诊所也在寻求能够将产品性能与实际疗效联繫起来的证据。本次研究将深入探讨影响骨关节炎疼痛治疗商业性和临床格局的治疗层级、给药途径趋势、分销动态以及病患细分。

骨关节炎疼痛领域在治疗方法选择、给药方式和证据要求方面正在经历重大的科学、临床和商业性变革。

受科学进步、支付方期望转变以及技术赋能的医疗模式的推动，骨关节炎的治疗格局正在发生显着变化。生物製剂和标靶小分子药物正在重塑治疗格局，而传统药物则不断提供能够提高耐受性和依从性的治疗选择。同时，数位健康平台和远端监测的出现使得对疼痛轨迹和功能改善的评估更加精准，有助于制定疗效评估方案和个人化治疗流程。

在商业性，製造商正透过策略联盟、专业合作和差异化市场策略来因应这一转变，优先发展高价值的临床细分市场。随着监管机构越来越依赖真实世界证据和加速核准，哪些候选药物能够获得持续应用将取决于它们能否产生可靠的核准后数据。此外，无菌注射剂生产和先进外用製剂技术的进步正在改变临床医生选择治疗方法的方式，从诊所到居家医疗，这使得围绕实际给药限制进行研发变得更加重要。

分析截至 2025 年的关税措施如何改变了骨关节炎治疗药物的供应链、生产布局和采购重点。

到2025年，累积贸易措施和不断变化的关税政策对骨关节炎治疗药物供应链、生产经济和筹资策略产生了多方面的影响。对关键中间体和成品进口征收更高的关税，加剧了依赖跨境原料药和辅料流通的企业的投入成本波动。因此，製造商和合约研发受託製造机构正在加快供应商多元化，扩大本地灌装能力，并重新审视长期采购协议，以降低关税引发的成本上涨风险。

除了成本之外，关税也在影响企业关于散装无菌製剂和特种製剂製造地地点的策略决策。注射剂需要严格的无菌製程和高效的低温运输物流，因此企业越来越倾向于在国内或邻近地区製造地，以减少跨境的复杂性。相反，常温保存的外用和口服药物则透过库存管理和选择性采购，获得了更大的灵活性，以应对关税相关的物流变化。支付方和医院采购团队正在加强对总到岸成本和供应韧性的审查，促使製造商提供更透明的供应链保证和紧急时应对计画。总而言之，2025年的关税趋势将强化韧性作为核心商业差异化因素的重要性，迫使企业调整製造地、筹资策略和定价模式，以适应不断变化的贸易状况。

可操作的细分洞察，揭示产品类型、给药途径、通路动态和患者群体如何系统性地决定临床定位和商业策略。

基于主导市场的骨关节炎治疗生态系统分析揭示了不同治疗层级和给药途径的产品策略所体现的独特临床和商业性行为。按产品类型划分，Cyclooxygenase-2抑制剂和非类固醇消炎剂是全身症状控制的基石，而皮质类固醇仍然是急性虚弱管理的首选药物，缓释製剂在长期症状控制中发挥着重要作用，粘稠补充剂则占据了关节内给药的特定领域，为寻求局部动态支持的患者提供服务。给药途径影响临床定位和应用动态，注射剂又细分为关节内注射（主要用于关节治疗）和肌肉注射（用于特定护理管道）；口服剂型分为胶囊、液体和片剂，以满足患者的依从性和剂量需求；局部疗法则以乳膏、凝胶和贴剂的形式提供，以满足其他疾病的患者或併发症的患者的需求。

分销管道的选择反映了购买行为和临床诊疗需求，既要兼顾医院药房的急性护理采购，又要兼顾零售药房的慢性病管理，同时还要拓展线上药房管道，以促进直接面向患者的销售和依从性管理项目。终端使用者细分揭示了不同的期望，例如诊所倾向于快速有效且与手术相容的药物，家庭医疗保健优先考虑长期治疗的易用性和安全性，而医院则优先考虑治疗严重的疗效和供应可靠性。不同年龄层（18岁以下青少年、18-64岁成人和65岁及以上老年人）的因素决定了製剂和剂量方面的优先顺序，其中老年人群需要更加关注合併症相互作用和多重用药问题。最后，疾病严重程度（轻度、中度和重度）与治疗强度和剂量直接相关，轻度患者需要局部或口服维持治疗，而重症患者则需要注射或联合治疗。这些细分为优先考虑研发投资、标籤定位和市场推广策略提供了一个多维框架。

区域战略资讯阐述了美洲、欧洲、中东和非洲以及亚太地区的动态将如何决定市场准入、应用和生产优先事项。

区域动态对临床应用、监管方式和供应链设计的影响在各大区域之间存在显着差异。在美洲，医疗系统和私人支付方对成本效益和持续功能获益证据的重视，加速了人们对能够显着改善行动能力并减少急诊医疗资源利用的治疗方法的兴趣。北美强大的生产能力和成熟的专业医疗基础设施支持了先进注射剂和联合治疗通讯协定的快速应用，而采购方面的严格审查则促使人们期望获得透明的供应保障。

在欧洲、中东和非洲，监管环境和报销机制的多样性要求企业制定有针对性的打入市场策略，使临床提案主张与当地的卫生技术评估框架和支付方的优先事项保持一致。欧洲、中东和非洲的某些市场也蕴藏着巨大的机会，可以与应对人口老化的公共卫生措施相结合，从而推动对更安全的慢性病治疗和社区医疗服务模式的需求。在亚太地区，人口结构的变化、专科诊所的快速扩张以及灵活的契约製造行业正在推动新型製剂的快速上市，但报销细分和准入差异仍然是限制因素。在整个全部区域，真实世界数据的互通性和本地生产投资仍然是决定企业优先推出产品和扩大生产线规模的关键因素。

公司层面的洞察，展现如何运用产品创新、伙伴关係和製造韧性来确保商业性和临床差异化。

骨关节炎疼痛领域的主要企业正在采取不同但互补的策略，以保持竞争力并实现临床差异化。许多企业正在投资研发新一代製剂，以增强药物对关节的标靶作用，同时降低全身暴露，进而提高老年患者和併发症患者的耐受性。生物技术开发商、专科药房和分销合作伙伴之间的策略联盟正被用于加速药物研发、提高患者依从性，并建立能够收集真实世界疗效数据的长期患者支援服务。

在营运方面，各公司正在加强无菌生产能力，降低供应链风险，并实现地域多元化，以更好地适应区域采购趋势。在商业性，各公司越来越重视透过卫生经济模型和结果研究来向医疗保健采购方和支付方展示价值。那些能够兼具临床差异化、供应链透明可靠以及清晰展现实际应用效果路径的公司，在临床和专业配药领域更具优势。

针对製造商和相关人员可采取的行动建议，旨在增强骨关节炎治疗的供应韧性、临床相关性以及与支付方目标一致的价值证明。

产业领导者应采取多管齐下的策略，以保持发展势头并应对短期挑战，同时建立长期竞争优势。首先，优先考虑供应商多元化，并投资于区域填充和无菌生产能力，以降低跨境贸易波动带来的风险，并满足医院对供应韧性的期望。其次，透过专注于开发能够提高老年人用药安全性、便于门诊给药并减轻居家看护者负担的製剂，使产品开发与实际临床需求相符。第三，加快产生将药物疗效与功能性结果和医疗资源利用联繫起来的真实世界证据，以支持与支付方的沟通以及基于结果的合约签订。

此外，企业应拓展数位互动和病患支援基础设施，以提高用药依从性，并持续收集疗效数据，从而指导产品迭代改进。商业策略应包括有针对性的通路优化，平衡医院药局的渗透率与零售药局和线上药局的覆盖范围，确保分销能同时满足急性治疗需求和慢性维持治疗需求。最后，应将情境规划纳入采购和定价策略，以便在不影响临床供应或策略上市时间表的前提下，应对关税变化、供应中断或报销政策调整。

对混合方法研究途径进行清晰描述，该方法整合了主要临床发现、次要资讯和基于情境的分析，以确保得出严谨且具有可操作性的研究结果。

本研究采用混合方法，结合一手研究、相关人员参与、有针对性的二手资讯和定量综合分析，得出可靠且可操作的结论。一手研究包括对风湿病学家、骨科医生、支付方、医院采购人员和高级商业主管进行结构化访谈，以了解治疗偏好、药品目录动态和采购驱动因素。二手资讯来自同行评审的临床文献、监管出版物、公共临床实验室註册库、专利申请和已验证的供应链资料库，以验证治疗趋势、研发管线活动和生产布局。

分析方法包括细分市场分析、情境分析（用于探讨供应中断和关税的影响）以及交叉验证技术（用于将观察到的采购行为与定性输入资料进行比对）。品质保证措施包括专家评审小组和调查方法审核，以确保各主题研究结果的一致性。这些方法将临床需求、分销实际情况和商业性考量连结起来，从而建立依证，为产品开发和市场准入提供切实可行的建议。

总结回顾：相关人员必须整合临床、商业性和营运方面的必要因素，才能在不断发展的骨关节炎治疗领域中取得成功。

总之，骨关节炎疼痛治疗领域的格局正因临床创新、不断演变的分销管道以及供应链的迫切需求而再形成，这些因素共同定义了新的商业性和临床成功阈值。有效的策略取决于透过标靶製剂和给药机制提供差异化的临床价值，同时展现对支付方和临床医生至关重要的真正功能性获益。在地化生产和透明的采购流程所体现的供应韧性，已成为商业性信誉中不可或缺的要素。

将研发组合与以患者为中心的治疗结果相结合、投资于循证医学研究并采用灵活的生产和分销模式的相关人员，将更有能力应对不断变化的市场环境。透过将这些策略重点纳入研发和商业化计划，企业可以更好地满足临床医生和患者的多元化需求，同时在动态的监管和商业环境中保持营运灵活性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 快速实施皮下单株抗NGF疗法可提高中重度骨关节炎疼痛缓解的持久性
  • 一种缓释型关节内水凝胶製剂的出现，可将膝关节炎的治疗效果延长至12週以上。
  • 由于患者偏好采用替代疗法来治疗慢性骨关节炎疼痛，低仿单标示外口服大麻素的非适应症使用正在增加。
  • 将穿戴式关节运动感测器与个人化疼痛管理应用程式结合的数位健康平台正在获得越来越多的投资。
  • 为了确保生物安全性并降低成本，抗TNF疗法在骨关节炎发炎治疗中生物相似药的研发越来越受欢迎。
  • 进行一项真实世界证据研究，以评估非阿片类镇痛药在不同骨关节炎患者群体中的相对疗效
  • 扩大非类固醇抗发炎药物与辅助性神经生长因子抑制剂的联合治疗，以最大限度地降低胃肠道和心血管风险。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的骨关节炎疼痛治疗市场

  • 皮质类固醇
  • Cyclooxygenase-2抑制剂
  • 非类固醇消炎剂
  • 用于缓解症状的促效剂
  • 黏稠补充剂

9. 依给药途径分類的骨关节炎疼痛治疗市场

  • 注射
    • 关节内
    • 肌肉内注射
  • 口服
    • 胶囊
    • 液体
    • 药片
  • 局部的
    • 奶油
    • 凝胶
    • 修补

第十章 骨关节炎疼痛治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 骨关节炎疼痛治疗市场（依最终用户划分）

  • 诊所
  • 家庭医疗保健
  • 医院

第十二章 依患者年龄层分類的骨关节炎疼痛治疗市场

  • 18岁以下的青少年
  • 18-64岁的成年人
  • 65岁及以上的老年人

第十三章 依疾病严重程度分類的骨关节炎疼痛治疗市场

  • 温和的
  • 缓和
  • 严重

第十四章 各地区骨关节炎疼痛治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 骨关节炎疼痛治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国骨关节炎疼痛治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Novartis AG
    • Bayer AG
    • Johnson & Johnson
    • Sanofi SA
    • GlaxoSmithKline plc
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Perrigo Company plc
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market is projected to grow by USD 14.33 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.54 billion
Estimated Year [2025] USD 9.12 billion
Forecast Year [2032] USD 14.33 billion
CAGR (%) 6.67%

A strategic introduction to the evolving osteoarthritis pain drug environment that frames clinical imperatives, patient diversity, and practical innovation pathways for stakeholders

Osteoarthritis remains a complex clinical challenge driven by heterogeneous patient needs, chronic pain trajectories, and variable functional impacts across age groups and disease severity. Clinicians and payers increasingly seek therapies that balance rapid symptom relief, safety for long-term use, and demonstrable effects on mobility and quality of life. Recent clinical innovation has focused on refining existing pharmacologic classes and exploring novel mechanisms to address persistent gaps in durable pain control and disease progression.

Against this backdrop, manufacturers are adapting development priorities to emphasize differentiated delivery formats, improved safety profiles for older adults, and solutions compatible with ambulatory and home-based care models. Concurrently, health systems and specialty clinics are demanding evidence that links product performance to real-world functional outcomes. This introduction sets the stage for a detailed examination of therapeutic classes, route-of-administration trends, distribution dynamics, and patient segmentation that together shape the commercial and clinical contours of the osteoarthritis pain drug space.

Transformative scientific, clinical, and commercial shifts reshaping therapeutic choices, delivery formats, and evidence expectations across the osteoarthritis pain landscape

The osteoarthritis drug landscape is undergoing transformative shifts driven by scientific advances, shifting payer expectations, and technology-enabled care models. Biologic approaches and targeted small molecules are redefining therapeutic possibilities, while formulation science continues to deliver options that improve tolerability and adherence. At the same time, the emergence of digital health platforms and remote monitoring is enabling more precise assessment of pain trajectories and functional improvement, which in turn supports outcomes-based contracting and personalized treatment algorithms.

Commercially, manufacturers are responding to these shifts through strategic alliances, specialty partnerships, and differentiated go-to-market strategies that prioritize high-value clinical niches. As regulatory pathways adapt to accommodate real-world evidence and accelerated approvals, the ability to generate robust post-authorization data will determine which candidates achieve sustainable uptake. In addition, ongoing improvements in sterile injectable manufacturing and advanced topical formulations are changing how clinicians select therapies across care settings, from clinics to home-based care, which reinforces the importance of aligning development with practical delivery constraints.

An analytical view of how tariff developments through 2025 have reshaped supply chains, manufacturing footprints, and procurement priorities across osteoarthritis therapeutics

The cumulative trade measures and tariff policy shifts introduced through 2025 have imparted a multifaceted impact on supply chains, manufacturing economics, and procurement strategies for osteoarthritis therapeutics. Increased duties on key intermediates and finished imports have elevated input cost volatility for companies reliant on cross-border API and excipient flows. As a direct consequence, manufacturers and contract development and manufacturing organizations have accelerated supplier diversification, expanded local fill-finish capacity, and reevaluated long-term sourcing agreements to mitigate exposure to tariff-driven cost escalation.

Beyond cost considerations, tariffs have influenced strategic decisions around where to locate high-volume sterile manufacturing versus specialized formulation work. Injectable therapies, which require stringent sterile processes and validated cold-chain logistics, have seen heightened attention to domestic or regionally proximate production to reduce cross-border complexity. Conversely, topical and oral formulations with longer shelf stability have provided more flexibility to absorb tariff-related logistics changes through inventory management and selective sourcing. Payers and hospital procurement teams have responded by intensifying scrutiny of total landed cost and supply resilience, prompting manufacturers to present more transparent supply chain assurances and contingency plans. In sum, tariff dynamics through 2025 have reinforced resilience as a core commercial differentiator, compelling companies to align manufacturing footprint, procurement strategies, and pricing models with evolving trade realities.

Actionable segmentation insights revealing how product types, administration routes, channel dynamics, and patient cohorts systematically determine clinical positioning and commercial strategy

A segmentation-led understanding of the osteoarthritis therapeutic ecosystem reveals distinct clinical and commercial behaviors that inform product strategy across therapeutic classes and delivery routes. In terms of product type, corticosteroids continue to be relied upon for acute flare management while cyclooxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs remain foundational for systemic symptom control, symptomatic slow-acting drugs serve niche roles in long-term symptom modulation, and viscosupplements occupy a specific intra-articular niche for patients seeking localized biomechanical support. Route of administration shapes clinical positioning and adoption dynamics, with injectable approaches subdividing into intra-articular options favored for targeted joint therapy and intramuscular formats used in specific care pathways, oral administration dividing into capsules, liquid formulations, and tablets to match adherence and dosing needs, and topical therapies offered as creams, gels, and patches that cater to safety-conscious or comorbid populations.

Distribution channel choices reflect purchasing behavior and care setting needs, balancing hospital pharmacy procurement for acute procedural use with retail pharmacy access for chronic management and growing online pharmacy channels that facilitate direct-to-patient fulfillment and adherence programs. End-user segmentation shows distinct expectations across clinics that favor rapid-onset, procedure-compatible options; home healthcare that prioritizes ease-of-use and safety for extended treatment; and hospitals that emphasize efficacy in severe presentations and supply reliability. Age-based considerations-adolescents under 18, adults 18 to 64, and elderly 65 plus-drive formulation and dosing priorities, with the elderly cohort demanding heightened attention to comorbidity interactions and polypharmacy. Finally, disease severity bands of mild, moderate, and severe map directly to therapeutic intensity and delivery format, where milder presentations trend toward topical and oral maintenance therapies and more severe disease necessitates injectable or combined modality strategies. Together, these segmentation dimensions provide a multidimensional framework to prioritize development investments, label positioning, and market access tactics.

Regional strategic intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics determine access, adoption, and manufacturing priorities

Regional dynamics are influencing clinical adoption, regulatory approaches, and supply chain design in markedly different ways across major geographies. In the Americas, health systems and private payers are focusing on cost-effectiveness and evidence of durable functional benefit, which accelerates interest in therapies that can demonstrate measurable improvements in mobility and reduced utilization of acute care resources. North American manufacturing capacity and a mature specialty care infrastructure support rapid adoption of advanced injectables and combination treatment protocols, while procurement scrutiny drives expectations for transparent supply assurances.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement mechanisms require targeted market access strategies that align clinical value propositions with local HTA frameworks and payer priorities. The EMEA region also presents significant opportunities to align public health initiatives with aging populations in certain markets, creating demand for safer chronic-use therapies and community-delivered care models. In the Asia-Pacific region, demographic shifts, rapid expansion of specialty clinics, and an agile contract manufacturing sector are fostering faster uptake of novel formulations, although fragmented reimbursement and variable access remain constraints. Across regions, interoperability of real-world data and regional manufacturing investments continue to be decisive factors shaping where companies prioritize launches and scale production lines.

Corporate-level insights showing how product innovation, partnerships, and manufacturing resilience are being deployed to secure commercial and clinical differentiation

Leading companies in the osteoarthritis pain space are pursuing distinct but complementary strategies to preserve competitiveness and capture clinical differentiation. Many are investing in next-generation formulations that reduce systemic exposure while enhancing targeted exposure at the joint, thereby improving tolerability for older adults and patients with comorbidities. Strategic alliances across biotech developers, specialty pharmacies, and distribution partners are being used to accelerate market entry and to build longitudinal patient support services that enhance adherence and gather real-world outcomes data.

On the operational front, firms are strengthening sterile manufacturing capabilities and pursuing geographic diversification to reduce supply chain risk and better align with regional procurement trends. Commercially, there is a growing emphasis on value demonstration through health economic modeling and targeted outcomes studies designed to speak to institutional buyers and payers. Firms that combine clinical differentiation with transparent supply chain credentials and a clear pathway to demonstrate real-world impact are establishing clearer routes to premium positioning within clinical formularies and specialist prescribing environments.

Actionable recommendations for manufacturers and stakeholders to enhance supply resilience, clinical relevance, and payer-aligned value demonstration in osteoarthritis therapeutics

Industry leaders should adopt a multifaceted approach to sustain momentum and address near-term disruptions while building long-term competitive advantage. First, prioritize supplier diversification and invest in regional fill-finish and sterile production capacity to reduce exposure to cross-border trade volatility and to meet hospital procurement expectations for supply resilience. Second, align product development with pragmatic clinical needs by focusing on formulations that improve safety for older adults, enable outpatient administration, and reduce caregiver burden in home healthcare settings. Third, accelerate generation of real-world evidence that links drug performance to functional outcomes and health resource utilization to support payer conversations and outcomes-based contracts.

Further, companies should expand digital engagement and patient support infrastructure to improve adherence and to capture continuous outcomes data that can inform iterative product improvements. Commercial strategies should include targeted channel optimization to balance hospital pharmacy penetration with retail and online pharmacy access, ensuring that distribution meets both acute procedural demand and chronic maintenance needs. Finally, embed scenario planning into procurement and pricing strategies so that tariff changes, supply disruptions, or reimbursement shifts can be accommodated without compromising clinical supply or strategic launch timelines.

Clear explanation of the mixed-methods research approach integrating primary clinical insights, secondary intelligence, and scenario-based analysis to ensure rigorous and actionable findings

This research applied a mixed-methods approach combining primary stakeholder engagement, targeted secondary intelligence, and quantitative synthesis to ensure robust and actionable conclusions. Primary research included structured interviews with practicing rheumatologists, orthopedic surgeons, payers, hospital procurement leads, and senior commercial executives to capture therapeutic preferences, formulary dynamics, and procurement drivers. Secondary inputs were drawn from peer-reviewed clinical literature, regulatory publications, public clinical trial registries, patent filings, and validated supply chain databases to triangulate therapeutic trends, pipeline activity, and manufacturing footprints.

Analytic methods incorporated segmentation mapping, scenario analysis to explore supply disruption and tariff impacts, and cross-validation techniques to reconcile qualitative inputs with observed procurement behaviors. Quality assurance included expert review panels and methodological audits to confirm consistency of thematic findings. Together, these approaches produced a defensible evidence base that links clinical needs, distribution realities, and commercial imperatives to practical recommendations for product development and market access.

Conclusive synthesis of clinical, commercial, and operational imperatives that stakeholders must integrate to succeed in the evolving osteoarthritis therapeutic arena

In conclusion, the osteoarthritis pain drug environment is being reshaped by clinical innovation, distribution evolution, and supply chain imperatives that together define new commercial and clinical thresholds for success. Effective strategies will hinge on delivering differentiated clinical value through targeted formulations and delivery mechanisms, while simultaneously demonstrating real-world functional benefits that matter to payers and clinicians. Supply resilience, evidenced by regional manufacturing and transparent procurement practices, has become a nonnegotiable element of commercial credibility.

Stakeholders who align development portfolios with patient-centric outcomes, invest in evidence generation, and adopt flexible manufacturing and distribution models will be best positioned to navigate the evolving landscape. By integrating these strategic priorities into development and commercialization plans, organizations can better meet the diverse needs of clinicians and patients while maintaining operational agility in a dynamic regulatory and trade environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of subcutaneous monoclonal anti-NGF therapies showing improved pain relief durability in moderate to severe osteoarthritis
  • 5.2. Emergence of sustained release intra-articular hydrogel formulations extending therapeutic effects beyond twelve weeks for knee osteoarthritis
  • 5.3. Growing off-label use of low-dose oral cannabinoids supported by patient preference for alternative chronic osteoarthritis pain management
  • 5.4. Escalating investment in digital health platforms integrating wearable joint motion sensors with personalized pain management apps
  • 5.5. Increasing prevalence of biosimilar development targeting biosafety and cost reduction in anti-TNF therapies for osteoarthritis inflammation
  • 5.6. Implementation of real-world evidence studies evaluating comparative effectiveness of non-opioid analgesics in diverse osteoarthritis populations
  • 5.7. Expansion of combination therapies pairing NSAIDs with adjunctive nerve growth factor blockers to minimize gastrointestinal and cardiovascular risks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Pain Drug Market, by Product Type

  • 8.1. Corticosteroids
  • 8.2. Cyclooxygenase 2 Inhibitors
  • 8.3. Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Symptomatic Slow Acting Drugs
  • 8.5. Viscosupplements

9. Osteoarthritis Pain Drug Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intra Articular
    • 9.1.2. Intramuscular
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Liquid
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Patch

10. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Osteoarthritis Pain Drug Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Osteoarthritis Pain Drug Market, by Patient Age Group

  • 12.1. Adolescents Under 18
  • 12.2. Adults 18 64
  • 12.3. Elderly 65+

13. Osteoarthritis Pain Drug Market, by Disease Severity

  • 13.1. Mild
  • 13.2. Moderate
  • 13.3. Severe

14. Osteoarthritis Pain Drug Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoarthritis Pain Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoarthritis Pain Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. Novartis AG
    • 17.3.3. Bayer AG
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Sanofi S.A.
    • 17.3.6. GlaxoSmithKline plc
    • 17.3.7. Viatris Inc.
    • 17.3.8. Teva Pharmaceutical Industries Ltd.
    • 17.3.9. Sandoz International GmbH
    • 17.3.10. Perrigo Company plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILL